Pharmaceutical company
Appears in 3 stories
Competitor with an already-approved SCLC treatment
Merck and Daiichi Sankyo withdrew their US application for ifinatamab deruxtecan, an experimental antibody-drug conjugate for extensive-stage small cell lung cancer, an aggressive disease that has resisted most new treatments. The FDA had told the companies their Phase 2 data were not enough to support accelerated approval, and the bid was pulled on September 25.
Updated Sep 29
Sponsor of the dazodalibep phase 3 program
Sjögren's disease has no approved treatment in the US. Amgen just moved a step closer to ending that.
Updated Sep 22
Developer of tarlatamab and originator of the BiTE platform
For decades, patients with extensive-stage small-cell lung cancer who relapsed after chemotherapy had almost nowhere to turn — five-year survival rates sat around 3%. Now a drug that bridges the patient's immune cells to their tumor has won approval in both the United States and China.
Updated May 31
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
